vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and PROCORE TECHNOLOGIES, INC. (PCOR). Click either name above to swap in a different company.
PROCORE TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($349.1M vs $284.0M, roughly 1.2× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -10.8%, a 107.1% gap on every dollar of revenue. On growth, PROCORE TECHNOLOGIES, INC. posted the faster year-over-year revenue change (15.6% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 13.8%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Procore Technologies is an American construction management software as a service company founded in 2002, with headquarters in Carpinteria, California. Procore hosts a platform to connect those involved in the construction industry on a global platform. The software allows for the creation of simplified workflows and displays a consolidated view of construction products that includes the tracking of tasks, management of project workflows, and scheduling.
ACAD vs PCOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $349.1M |
| Net Profit | $273.6M | $-37.6M |
| Gross Margin | 90.8% | 80.1% |
| Operating Margin | 6.1% | -12.3% |
| Net Margin | 96.3% | -10.8% |
| Revenue YoY | 9.4% | 15.6% |
| Net Profit YoY | 90.3% | 39.6% |
| EPS (diluted) | $1.61 | $-0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $349.1M | ||
| Q3 25 | $278.6M | $338.9M | ||
| Q2 25 | $264.6M | $323.9M | ||
| Q1 25 | $244.3M | $310.6M | ||
| Q4 24 | $259.6M | $302.0M | ||
| Q3 24 | $250.4M | $295.9M | ||
| Q2 24 | $242.0M | $284.3M | ||
| Q1 24 | $205.8M | $269.4M |
| Q4 25 | $273.6M | $-37.6M | ||
| Q3 25 | $71.8M | $-9.1M | ||
| Q2 25 | $26.7M | $-21.1M | ||
| Q1 25 | $19.0M | $-33.0M | ||
| Q4 24 | $143.7M | $-62.3M | ||
| Q3 24 | $32.8M | $-26.4M | ||
| Q2 24 | $33.4M | $-6.3M | ||
| Q1 24 | $16.6M | $-11.0M |
| Q4 25 | 90.8% | 80.1% | ||
| Q3 25 | 92.2% | 79.7% | ||
| Q2 25 | 92.2% | 79.1% | ||
| Q1 25 | 91.7% | 79.1% | ||
| Q4 24 | 91.6% | 81.2% | ||
| Q3 24 | 92.5% | 81.4% | ||
| Q2 24 | 92.5% | 83.1% | ||
| Q1 24 | 88.8% | 83.0% |
| Q4 25 | 6.1% | -12.3% | ||
| Q3 25 | 12.8% | -4.4% | ||
| Q2 25 | 12.2% | -9.3% | ||
| Q1 25 | 7.9% | -11.7% | ||
| Q4 24 | 59.1% | -21.9% | ||
| Q3 24 | 12.6% | -12.3% | ||
| Q2 24 | 12.6% | -5.2% | ||
| Q1 24 | 7.4% | -7.0% |
| Q4 25 | 96.3% | -10.8% | ||
| Q3 25 | 25.8% | -2.7% | ||
| Q2 25 | 10.1% | -6.5% | ||
| Q1 25 | 7.8% | -10.6% | ||
| Q4 24 | 55.4% | -20.6% | ||
| Q3 24 | 13.1% | -8.9% | ||
| Q2 24 | 13.8% | -2.2% | ||
| Q1 24 | 8.0% | -4.1% |
| Q4 25 | $1.61 | $-0.25 | ||
| Q3 25 | $0.42 | $-0.06 | ||
| Q2 25 | $0.16 | $-0.14 | ||
| Q1 25 | $0.11 | $-0.22 | ||
| Q4 24 | $0.86 | $-0.42 | ||
| Q3 24 | $0.20 | $-0.18 | ||
| Q2 24 | $0.20 | $-0.04 | ||
| Q1 24 | $0.10 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $768.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $1.3B |
| Total Assets | $1.6B | $2.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $768.5M | ||
| Q3 25 | $258.0M | $684.0M | ||
| Q2 25 | $253.6M | $620.9M | ||
| Q1 25 | $217.7M | $566.7M | ||
| Q4 24 | $319.6M | $775.4M | ||
| Q3 24 | $155.1M | $756.9M | ||
| Q2 24 | $177.1M | $735.4M | ||
| Q1 24 | $204.7M | $744.6M |
| Q4 25 | $1.2B | $1.3B | ||
| Q3 25 | $917.3M | $1.2B | ||
| Q2 25 | $822.4M | $1.2B | ||
| Q1 25 | $765.2M | $1.2B | ||
| Q4 24 | $732.8M | $1.3B | ||
| Q3 24 | $577.2M | $1.3B | ||
| Q2 24 | $516.7M | $1.3B | ||
| Q1 24 | $464.0M | $1.2B |
| Q4 25 | $1.6B | $2.2B | ||
| Q3 25 | $1.3B | $2.1B | ||
| Q2 25 | $1.2B | $2.0B | ||
| Q1 25 | $1.1B | $1.9B | ||
| Q4 24 | $1.2B | $2.1B | ||
| Q3 24 | $976.9M | $2.0B | ||
| Q2 24 | $914.1M | $2.0B | ||
| Q1 24 | $855.1M | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $114.9M |
| Free Cash FlowOCF − Capex | — | $109.2M |
| FCF MarginFCF / Revenue | — | 31.3% |
| Capex IntensityCapex / Revenue | — | 1.6% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $282.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $114.9M | ||
| Q3 25 | $74.3M | $88.5M | ||
| Q2 25 | $64.0M | $30.8M | ||
| Q1 25 | $20.3M | $66.0M | ||
| Q4 24 | $40.4M | $29.1M | ||
| Q3 24 | $63.2M | $39.3M | ||
| Q2 24 | $25.0M | $58.7M | ||
| Q1 24 | $29.1M | $69.1M |
| Q4 25 | — | $109.2M | ||
| Q3 25 | $73.9M | $83.1M | ||
| Q2 25 | — | $27.9M | ||
| Q1 25 | — | $62.0M | ||
| Q4 24 | — | $17.4M | ||
| Q3 24 | $63.2M | $35.7M | ||
| Q2 24 | — | $56.8M | ||
| Q1 24 | — | $67.1M |
| Q4 25 | — | 31.3% | ||
| Q3 25 | 26.5% | 24.5% | ||
| Q2 25 | — | 8.6% | ||
| Q1 25 | — | 20.0% | ||
| Q4 24 | — | 5.8% | ||
| Q3 24 | 25.2% | 12.1% | ||
| Q2 24 | — | 20.0% | ||
| Q1 24 | — | 24.9% |
| Q4 25 | — | 1.6% | ||
| Q3 25 | 0.1% | 1.6% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 3.9% | ||
| Q3 24 | 0.0% | 1.2% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
PCOR
| US | $298.3M | 85% |
| Non Us | $50.9M | 15% |
